CNS
Expertise in CNS across the main assets shaping the industry
Services
From established generics, new innovators to newer links such as metabolic, Intellia posses a wide range of expertise in the CNS landscape
Analysis & Monitoring
In-depth market analysis and reporting through proprietary databases and algorithms tracking the most important assets in Alzheimers, schizophrenia, migraine, bi-polar disorder and other key therapeutic disease areas.
Detailed asset scan of all Phase 1, 2, and 3 assets across several indications and focus migraine; comprehensive Post launch Market Access and P&MA diligence conducted on priority assets
Consulting
Expert consulting for strategic market decisions, advised by a team of experts with over 20 years of combined experience in Pharmaceutical/Biotech and CNS.
Comprehensive launch strategy, including market assessment, customer segmentation, positioning, value proposition, pricing, and market access.
Sample Projects
Recently Conducted Projects
ECNP Conference Coverage
Conference Coverage with the use of AI in pre-post conference content
CNS Mid-Cap Due Dilligence
Comprehensive company evaluations in CNS with schizophrenia and migraine asset review
Recent Relevant Therapeutic Areas Include:
Associated Agitation
Alzheimer’s disease
Bipolar Disease
Dementia
Depression
Epilepsy
Meningitis
Migraine
Multiple sclerosis
Muscular dystrophy/atrophy
Neuropathy/neuropathic pain
Parkinson’s disease
Schizophrenia
★★★★★
Contact Us
Get in touch for insights.
